These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 1810203)

  • 1. In vitro activities of cefepime alone and with amikacin against aminoglycoside-resistant gram-negative bacteria.
    Fung-Tomc J; Huczko E; Kolek B; Thater C; Kessler RE
    Antimicrob Agents Chemother; 1991 Dec; 35(12):2652-4. PubMed ID: 1810203
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative antimicrobial activity of FK037, cefpirome, ceftazidime and cefepime against aminoglycoside-sensitive and aminoglycoside-resistant Pseudomonas aeruginosa and Pseudomonas spp.
    Baltch AL; Smith RP; Ritz W
    Chemotherapy; 1994; 40(6):391-8. PubMed ID: 7842822
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multicentre comparative study on the antibacterial activity of FK-037, a new parenteral cephalosporin.
    Martínez-Beltrán J; Cantón R; Liñares J; García de Lomas J; Gimeno C; Tubau F; Baquero F
    Eur J Clin Microbiol Infect Dis; 1995 Mar; 14(3):244-52. PubMed ID: 7614970
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activity of cefepime against ceftazidime- and cefotaxime-resistant gram-negative bacteria and its relationship to beta-lactamase levels.
    Fung-Tomc J; Dougherty TJ; DeOrio FJ; Simich-Jacobson V; Kessler RE
    Antimicrob Agents Chemother; 1989 Apr; 33(4):498-502. PubMed ID: 2499250
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aminoglycosides plus beta-lactams against gram-negative organisms. Evaluation of in vitro synergy and chemical interactions.
    Giamarellou H
    Am J Med; 1986 Jun; 80(6B):126-37. PubMed ID: 3088998
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative in vitro activity of cefepime and four extended-spectrum beta-lactams on 1,251 aminoglycoside-resistant gram-negative hospital strains.
    Vanhoof R; Nulens E; Nyssen HJ; Hannecart-Pokorni E
    Chemotherapy; 1992; 38(4):225-31. PubMed ID: 1473361
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative in vitro bactericidal activity between cefepime and ceftazidime, alone and associated with amikacin, against carbapenem-resistant Pseudomonas aeruginosa strains.
    Bantar C; Di Chiara M; Nicola F; Relloso S; Smayevsky J
    Diagn Microbiol Infect Dis; 2000 May; 37(1):41-4. PubMed ID: 10794939
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the in vitro activity of six broad-spectrum beta-lactam antimicrobial agents tested against over 2,000 clinical isolates from 22 medical centers in Japan. Japan Antimicrobial Resistance Study Group.
    Yamaguchi K; Mathai D; Biedenbach DJ; Lewis MT; Gales AC; Jones RN
    Diagn Microbiol Infect Dis; 1999 Jun; 34(2):123-34. PubMed ID: 10354863
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antimicrobial activity of cefepime tested against ceftazidime-resistant Gram-negative clinical strains from North American Hospitals: report from the SENTRY Antimicrobial Surveillance Program (1998-2004).
    Pfaller MA; Sader HS; Fritsche TR; Jones RN
    Diagn Microbiol Infect Dis; 2006 Sep; 56(1):63-8. PubMed ID: 16650951
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative in vitro activity of cefepime (BMY 28142) against multiresistant nosocomial isolates of Pseudomonas aeruginosa.
    Voutsinas D; Mavroudis T; Avlamis A; Giamarellou H
    Eur J Clin Microbiol Infect Dis; 1989 Oct; 8(10):917-9. PubMed ID: 2512141
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potency and spectrum trends for cefepime tested against 65746 clinical bacterial isolates collected in North American medical centers: results from the SENTRY Antimicrobial Surveillance Program (1998-2003).
    Sader HS; Fritsche TR; Jones RN
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):265-73. PubMed ID: 16105569
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In-vitro activity of cefepime and other broad-spectrum antimicrobials against several groups of gram-negative bacilli and Staphylococcus aureus.
    Tallis E; Rudensky B; Attias D; Raveh D; Schlesinger Y; Yinnon AM
    Diagn Microbiol Infect Dis; 1999 Oct; 35(2):121-6. PubMed ID: 10579092
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multicenter comparison of in vitro activities of FK-037, cefepime, ceftriaxone, ceftazidime, and cefuroxime.
    Washington JA; Jones RN; Gerlach EH; Murray PR; Allen SD; Knapp CC
    Antimicrob Agents Chemother; 1993 Aug; 37(8):1696-700. PubMed ID: 8215286
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro activity of BMY-28142 in comparison with those of other beta-lactam antimicrobial agents.
    Tsuji A; Maniatis A; Bertram MA; Young LS
    Antimicrob Agents Chemother; 1985 Apr; 27(4):515-9. PubMed ID: 3839120
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro evaluation of cefepime and other broad-spectrum beta-lactams in Taiwan medical centers. The Taiwan Antimicrobial Resistance Study Group.
    Biedenbach DJ; Johnson DM; Jones RN
    Diagn Microbiol Infect Dis; 1999 Dec; 35(4):299-305. PubMed ID: 10668589
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro evaluation of cefepime and other broad-spectrum beta-lactams against bacteria from Indonesian medical centers. The Indonesia Antimicrobial Resistance Study Group.
    Lewis MT; Biedenbach DJ; Jones RN
    Diagn Microbiol Infect Dis; 1999 Dec; 35(4):285-90. PubMed ID: 10668587
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparisons of parenteral broad-spectrum cephalosporins tested against bacterial isolates from pediatric patients: report from the SENTRY Antimicrobial Surveillance Program (1998-2004).
    Jones RN; Sader HS; Fritsche TR; Pottumarthy S
    Diagn Microbiol Infect Dis; 2007 Jan; 57(1):109-16. PubMed ID: 16930923
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro activity of BRL 36650, a new penicillin.
    Van Landuyt HW; Lambert A; Boelaert J; Gordts B
    Antimicrob Agents Chemother; 1986 Feb; 29(2):362-6. PubMed ID: 3087281
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro activity of cefepime and cefpirome compared to other third-generation cephem antibiotics against gram-negative nosocomial pathogens.
    Tumah HN
    Pharmazie; 2004 Nov; 59(11):854-8. PubMed ID: 15587586
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In-vitro activity of FK 037 (Cefoselis), a novel 4(th) generation cephalosporin, compared to cefepime and cefpirome on nosocomial staphylococci and gram-negative isolates.
    Giamarellos-Bourboulis EJ; Grecka P; Tsitsika A; Tympanidou C; Giamarellou H
    Diagn Microbiol Infect Dis; 2000 Mar; 36(3):185-91. PubMed ID: 10729661
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.